APOLLOMICS INC. CLASS A ORDINARY SHARES
NASDAQ: APLM (Apollomics Inc.)
Last update: 1 hour ago20.69
-0.11 (-0.53%)
| Previous Close | 20.80 |
| Volume | 36,509 |
| Price / Sales | 3.40 |
| 52 Weeks Range |
| Operating Margin (TTM) | 1,007.39% |
| Diluted EPS (TTM) | -52.80 |
| Quarterly Revenue Growth (YOY) | 262.30% |
| Total Debt/Equity (MRQ) | 19.86% |
| Current Ratio (MRQ) | 1.39 |
| Operating Cash Flow (TTM) | -28.74 M |
| Levered Free Cash Flow (TTM) | -14.94 M |
| Return on Assets (TTM) | -75.07% |
| Return on Equity (TTM) | -233.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Apollomics Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | -1.4 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -1.81 |
Select this tab to load the latest available analysis.
|
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 36.50% |
| % Held by Institutions | 0.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Citigroup Inc | 30 Jun 2026 | 0 |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |